Clinical trials are underway for small-molecule correctors that aim to treat ADPKD in patients with a subset of PKD1 gene variants by correcting defective protein folding to restore function (as reviewed in ref. 68), but the efficacy will need to be evaluated against patients with PKD2 variants. The gene discussed is PKD2; the disease is autosomal dominant polycystic kidney disease.